- $137.05m
- -$42.83m
Leerink Partners cuts Compass Therapeutics to 'market perform'
U.S. RESEARCH ROUNDUP- Apollo, Blackstone, Hershey
Brief: Compass Therapeutics Announces CEO Transition
U.S. RESEARCH ROUNDUP- Akoya Biosciences, Boston Beer Company, Victory Capital Holdings
Brief: Compass Therapeutics Receives FDA Fast Track Designation For The Investigation Of CTX-009 In Combination With Paclitaxel
Brief: Compass Therapeutics Announces First Patient Dosed In Phase 1 Study Of CTX-8371
Brief: Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
Brief: Compass Therapeutics - Ended 2023 With Estimated $152 Million In Cash, Marketable Securities
Brief: Adage Capital Partners, L.P. Reports 5.66% Passive Stake In Compass Therapeutics
Brief: Compass Therapeutics Q3 basic EPS USD -0.08
Brief: Compass Therapeutics Reports Second Quarter 2023 Financial Results
Brief: Compass Therapeutics posts Q2 basic EPS USD -0.09
Brief: Compass Therapeutics To Be Added To The Russell 2000 And Russell 3000 Indexes
Brief: Compass Therapeutics Inc Ended Q1 With $175 Million In Cash And Marketable Securities
Brief: Compass Therapeutics Reports Q4 Net Loss Of $0.10 Per Share
Brief: Compass Therapeutics Inc Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank
U.S. RESEARCH ROUNDUP-Eastern Bankshares, Fibrogen, Nu Skin Enterprises
Brief: Compass Therapeutics Announces Phase 2 Data Of CTX-009 Will Be Presented At ASCO GI Cancers Symposium
Brief: Compass Therapeutics Files Prospectus Relates To Offering And Resale Of Up To 25 Million Shares